BEING in the royal family has its perks – particularly when it comes to fancy gifts from relatives. Princess Kate has been ...

It can take years for prostate cancer to turn castration-resistant, when cancer cells stop responding to hormonal therapy.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment prolongs survival.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Optilume system improves urinary flow and reduces urinary symptoms without affecting sexual function in men with benign ...

Sumitomo Pharma America, Inc. (SMPA) presented new, positive data from the COURAGE Phase 3 open-label extension study of vibegron (GEMTESA®) in men living with overactive bladder (OAB) and receiving ...

Lancashire Teaching Hospitals NHS Foundation Trust is celebrating a major milestone, having completed its 1,000th ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

Medtronic confirmed that its Hugo surgical robot system has been submitted to the FDA for review, alongside the successful completion of a large clinical trial evaluating its performance | According ...

Penn Medicine celebrated the groundbreaking of the Roberts Proton Therapy Center at Penn Presbyterian Medical Center in ...

Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration ...

Cumberland Medical Center is the first in East Tennessee and the Upper Cumberland region to introduce new robotic technology ...